NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free SRZN Stock Alerts $10.00 -0.10 (-0.99%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$10.00▼$10.1050-Day Range$8.61▼$15.7152-Week Range$4.50▼$16.19Volume736 shsAverage Volume13,350 shsMarket Capitalization$32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Surrozen alerts: Email Address Surrozen MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($9.19) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector3637th out of 5,424 stocksBiological Products, Except Diagnostic Industry580th out of 909 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Surrozen. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.89% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surrozen has recently increased by 358.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SRZN. Previous Next 1.1 News and Social Media Coverage Search Interest1 people have searched for SRZN on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Surrozen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,999,994.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders35.00% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Surrozen are expected to grow in the coming year, from ($9.19) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surrozen is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surrozen is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurrozen has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Surrozen Stock (NASDAQ:SRZN)Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Read More SRZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRZN Stock News HeadlinesApril 9, 2024 | insidertrades.comInsider Buying: Surrozen, Inc. (NASDAQ:SRZN) Director Buys 193,548 Shares of StockApril 18, 2024 | msn.comSurrozen files to sell 1.09M shares of common stock for holdersMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 18, 2024 | msn.comSurrozen (SRZN) Price Target Decreased by 40.00% to 20.66April 10, 2024 | uk.investing.comSurrozen director Tim Kutzkey acquires $3m in company stockApril 3, 2024 | globenewswire.comSurrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisApril 1, 2024 | msn.comU.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | msn.comWhy Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?May 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 1, 2024 | globenewswire.comSurrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043April 1, 2024 | globenewswire.comSurrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq RulesFebruary 8, 2024 | msn.comSurrozen Promotes Charles Williams to COO with CFO RoleJanuary 18, 2024 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides Corporate Update on Clinical ProgramsJanuary 18, 2024 | ca.finance.yahoo.comSurrozen, Inc. (SRZNW) Stock Price, News, Quote & History - Yahoo FinanceJanuary 18, 2024 | finance.yahoo.comSurrozen Provides Corporate Update on Clinical ProgramsJanuary 3, 2024 | finance.yahoo.comWe're Keeping An Eye On Surrozen's (NASDAQ:SRZN) Cash Burn RateNovember 10, 2023 | stocknews.com3 Biotech Stocks to Watch in NovemberNovember 9, 2023 | msn.comSurrozen GAAP EPS of -$0.34 misses by $0.03November 8, 2023 | finance.yahoo.comSurrozen Provides Third Quarter 2023 Financial ResultsNovember 4, 2023 | morningstar.comSurrozen Inc Ordinary Shares SRZNAugust 20, 2023 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides Second Quarter 2023 Financial ResultsAugust 10, 2023 | msn.comSurrozen GAAP EPS of -$0.31August 9, 2023 | finance.yahoo.comSurrozen Provides Second Quarter 2023 Financial ResultsJuly 21, 2023 | finance.yahoo.comIs Surrozen (NASDAQ:SRZN) In A Good Position To Deliver On Growth Plans?June 5, 2023 | finance.yahoo.comSurrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic StrokeMay 15, 2023 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline UpdatesMay 13, 2023 | msn.comSurrozen GAAP EPS of -$0.48 misses by $0.07See More Headlines Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/04/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SRZN CUSIPN/A CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees42Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.3914) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-82.43% Return on Assets-69.74% Debt Debt-to-Equity RatioN/A Current Ratio5.75 Quick Ratio5.75 Sales & Book Value Annual Sales$12.50 million Price / Sales2.56 Cash FlowN/A Price / Cash FlowN/A Book Value$18.39 per share Price / Book0.54Miscellaneous Outstanding Shares3,200,000Free Float2,079,000Market Cap$32 million OptionableNot Optionable Beta0.88 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Craig C. Parker M.B.A. (Age 62)CEO, President & Director Comp: $825.32kMr. Charles Williams (Age 44)CFO, COO & Corporate Secretary Comp: $611.03kDr. Li Yang Ph.D. (Age 55)Executive Vice President of Research Comp: $535.46kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Roeland Nusse Ph.D. (Age 74)Co-Founder & Member of Scientific Advisory Board Dr. Calvin Kuo M.D.Ph.D., Co-Founder & Member of Scientific AdvisorEsther JhunControllerMore ExecutivesKey CompetitorsNKGen BiotechNYSE:NKGNMiNK TherapeuticsNASDAQ:INKTProtara TherapeuticsNASDAQ:TARAIN8bioNASDAQ:INABCortexymeNASDAQ:CRTXView All CompetitorsInsiders & InstitutionsTim KutzkeyBought 193,548 shares on 4/4/2024Total: $3.00 M ($15.50/share)Board of Trustees of The Leland Stanford Junior UniversitySold 729,829 shares on 2/15/2024Ownership: 2.557%Column Group LLCSold 8,787,144 shares on 2/9/2024Ownership: 30.767%View All Insider TransactionsView All Institutional Transactions SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed in 2024? Surrozen's stock was trading at $9.40 at the start of the year. Since then, SRZN shares have increased by 6.4% and is now trading at $10.00. View the best growth stocks for 2024 here. Are investors shorting Surrozen? Surrozen saw a increase in short interest in April. As of April 15th, there was short interest totaling 36,200 shares, an increase of 358.2% from the March 31st total of 7,900 shares. Based on an average daily trading volume, of 16,700 shares, the short-interest ratio is currently 2.2 days. Currently, 1.9% of the shares of the stock are sold short. View Surrozen's Short Interest. When is Surrozen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SRZN earnings forecast. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) posted its quarterly earnings results on Monday, November, 15th. The company reported ($7.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.85) by $1.80. When did Surrozen's stock split? Shares of Surrozen reverse split on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRZN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
